

19 March 2026

ASX Announcement

Firebrick to present at NWR Virtual Healthcare Conference

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

Executive Chair Dr Peter Molloy will present at **10:30am AEDT on Thursday 26 March 2026**.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

https://us02web.zoom.us/webinar/register/WN_CoM2BteGTzaQ9nh1Zczm_w

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to:

matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine® Throat Spray is the first follow-on product, now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and plans to expand sales to up to 10 markets over three years, including the Philippines. For further information, visit firebrickpharma.com.

Contacts:

Media contact:

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com